Business Description
Annexin Pharmaceuticals AB
ISIN : SE0009664154
Description
Annexin Pharmaceuticals AB is a biotechnology company. It is developing biological drug candidate ANXV, a recombinant human protein Annexin A5 for treatment of various cardiovascular diseases. The company also focuses on development of ANXV for the treatment of retinal vein occlusion.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.88 | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 11.6 | |||||
| 3-Year EPS without NRI Growth Rate | 12.5 | |||||
| 3-Year FCF Growth Rate | 8.9 | |||||
| 3-Year Book Growth Rate | -29.7 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 56.25 | |||||
| 9-Day RSI | 53.72 | |||||
| 14-Day RSI | 51.32 | |||||
| 6-1 Month Momentum % | 155.26 | |||||
| 12-1 Month Momentum % | 50.39 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 7.66 | |||||
| Quick Ratio | 7.66 | |||||
| Cash Ratio | 7.3 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -38.2 | |||||
| Shareholder Yield % | -17.32 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -301.72 | |||||
| ROA % | -210.54 | |||||
| ROIC % | -803.48 | |||||
| ROC (Joel Greenblatt) % | -4588.83 | |||||
| ROCE % | -301.94 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 10.38 | |||||
| EV-to-EBIT | -4.59 | |||||
| EV-to-EBITDA | -4.59 | |||||
| EV-to-FCF | -4.46 | |||||
| Earnings Yield (Greenblatt) % | -21.81 | |||||
| FCF Yield % | -19.73 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Annexin Pharmaceuticals AB Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -0.016 | ||
| Beta | 0 | ||
| Volatility % | 137.21 | ||
| 14-Day RSI | 51.32 | ||
| 14-Day ATR (€) | 0.001811 | ||
| 20-Day SMA (€) | 0.0323 | ||
| 12-1 Month Momentum % | 50.39 | ||
| 52-Week Range (€) | 0.0108 - 0.0646 | ||
| Shares Outstanding (Mil) | 532.98 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Annexin Pharmaceuticals AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Annexin Pharmaceuticals AB Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Annexin Pharmaceuticals AB Frequently Asked Questions
What is Annexin Pharmaceuticals AB(FRA:Q91)'s stock price today?
The current price of FRA:Q91 is €0.03. The 52 week high of FRA:Q91 is €0.06 and 52 week low is €0.01.
When is next earnings date of Annexin Pharmaceuticals AB(FRA:Q91)?
The next earnings date of Annexin Pharmaceuticals AB(FRA:Q91) is 2025-02-06.
Does Annexin Pharmaceuticals AB(FRA:Q91) pay dividends? If so, how much?
Annexin Pharmaceuticals AB(FRA:Q91) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers